Lymphoma hub

New publication📝 Results from a phase Ib/II trial, published in the Journal of Clinical Oncology, show Glofit-Pola achieved 78.3% ORR in heavily pretreated R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy.

Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd

Francesc Bosch discussed factors influencing fixed-duration BTKi + BCL-2i treatment selection for patients with CLL.

Listen here: https://loom.ly/rOxk8hM

#leusm #lymsm #MedNews #MedEd

New publication📝2-year follow-up results from the RELIANCE trial, published in The British Journal of Haematology, show that relma-cel was associated with a CR rate of 96.3% in patients with R/R FL.

Learn more: https://loom.ly/uiZeapw

#lymphoma #CART #lymsm #MedNews #MedEd

Francesc Bosch discussed factors influencing the use of fixed-duration therapy for patients with CLL.

Watch the full video here: https://loom.ly/29aw1Zs

#leusm #lymsm #MedNews #MedEd

New data 📝 Results from studies of real-world outcomes and CD19 expression following tafasitamab treatment in patients with R/R DLBCL may guide the sequencing of CD19-directed therapies in this patient population.

Learn more: https://loom.ly/6s-ODz0

#lymphoma #lymsm #MedNews #MedEd

New publication 📝 Results from the phase II FIL_V-RBAC trial, published in Lancet Haematology, show venetoclax added to RBAC was associated with a 2-year PFS rate of 60% in older patients with high-risk MCL.

Learn more: https://loom.ly/EiJNbmg

#lymphoma #lymsm #MedNews #MedEd

What factors influence BTKi + BCL-2i treatment selection for patients with CLL? The Lymphoma Hub was pleased to speak to Francesc Bosch, University Hospital Vall d’Hebron, about the use of fixed-duration therapy in CLL.

Watch here: https://loom.ly/29aw1Zs

#leusm #lymsm #MedNews #MedEd

New publication 📝 Phase II/II ENRICH trial results, published in The Lancet, show ibrutinib + rituximab improves PFS vs immunochemotherapy in older patients with previously untreated MCL (HR, 0.69; 95% CI, 0.52–0.90; p = 0.0034).

Learn more: LymphomaHub.com

#lymsm #lymphoma #MedNews #MedEd

Francesc Bosch, University Hospital Vall d’Hebron, discussed factors influencing BTKi + BCL-2i treatment selection for patients with CLL.

Watch here: https://loom.ly/29aw1Zs

#leusm #lymsm #MedNews #MedEd

New publication 📝 Results from the phase III SUNMO trial, published in the Journal of Clinical Oncology, show Mosun-Pola significantly improved PFS (11.5 vs 3.8 months) and ORR (70% vs 40%) vs R-GemOx in transplant-ineligible R/R LBCL.

Learn more: LymphomaHub.com

#lymsm #lymphoma #MedNews #MedEd

New publication📝Phase II results, published in Blood, show zanubrutinib + rituximab + lenalidomide was associated with a 65% CR rate, 2-year PFS of 67.1%, and 2-year OS of 82.4% in patients aged ≥75 years with de novo DLBCL.

Learn more: LymphomaHub.com

#DLBCL #lymphoma #lymsm #MedNews #MedEd

New publication 📝 Data published in The Journal of Clinical Oncology show ctDNA detection at EOT strongly predicts outcomes in LBCL, with detectable ctDNA MRD associated with 2-year PFS of 29% vs 97% for undetectable MRD.

Learn more: LymphomaHub.com

#lymphoma #lymsm #ctDNA #MedNews #MedEd

Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the randomized phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.

Watch the full video here: https://loom.ly/FdLag2Q

#lymsm #lymphoma #MedNews #MedEd

Catch up on the latest developments in lymphoma and CLL with our coverage from #IACH 2025: https://loom.ly/VEha6BE
#lymphoma #lymsm #leusm #MedNews #MedEd

New publication 📝 Phase III results, published in Blood, show acalabrutinib + obinutuzumab significantly improved PFS and OS vs chlorambucil + obinutuzumab in treatment-naïve CLL (72-month PFS, 78.0% vs 17.2%; p < 0.0001).

Learn more: LymphomaHub.com

#CLLsm #leusm #MedNews #MedEd

🚨 NEWS 🚨
FDA grants fast track designation to EO2463, an ‘OncoMimic’ immunotherapy, for the treatment of patients with FL in the low tumor burden “watch-and-wait” setting.
Read more: https://loom.ly/jx-bpb4

#lymsm #lymphoma #MedNews #MedEd

Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.

Listen here: https://loom.ly/1ncUMzw

#lymsm #lymphoma #MedNews #MedEd

New publication 📝 Results from the phase II COALITION, published in Journal of Clinical Oncology, show glofitamab in combination with R-CHOP or Pola-R-CHP was feasible and safe, with durable responses in patients with LBCL.

Learn more: LymphomaHub.com

#Lymphoma #lymsm #MedNews #MedEd

🚨 NEWS 🚨
FDA grants breakthrough therapy designation to sonrotoclax, a next-generation BCL-2 inhibitor, for the treatment of R/R MCL, based on results from the BGB-11417-201 trial.
Read more: https://loom.ly/AfWxP3A
#lymsm #leusm #MedNews #MedEd

New data 📝 At #EHA2025 and #18ICML, Matthew Ku and Krish Patel, respectively, presented results from a phase Ib study investigating JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy, in patients with R/R LBCL.

Learn more: https://loom.ly/bobViGE

#Lymphoma #lymsm #MedNews #MedEd

New publication 📝 Phase I/II results, published in Blood Advances, show pirtobrutinib achieved 52.1% ORR in patients with R/R FL, with median DoR of 10.2 months and favorable tolerability.

Learn more: https://loom.ly/DEFIgFo

#lymsm #lymphoma #MedNews #MedEd

What are the latest updates from the phase III STARGLO trial? The Lymphoma Hub spoke to Charles Herbaux, University of Montpellier, about the 2L and 3L+ data from this trial.

Watch here: https://loom.ly/FdLag2Q

#lymsm #lymphoma #MedNews #MedEd

Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ outcomes from the randomized phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.

Watch here: https://loom.ly/FdLag2Q

#lymsm #lymphoma #MedNews #MedEd

New publication 📝 Phase II PILOT study results, published in Blood Advances, show liso-cel is an effective second-line therapy for patients with LBCL, with an ORR of 80%.

Learn more: https://loom.ly/qCzLBcA

#lymphoma #MedNews #MedEd

🚨 NEWS 🚨
FDA grants fast track designation to UB-VV111, an off-the-shelf gene therapy that generates CD19-directed CAR T cells in vivo, for the treatment of R/R LBCL or CLL after ≥2 prior lines of therapy.
Read more: https://loom.ly/xeSW0c4
#lymsm #leusm #MedNews #MedEd

New publication 📝Phase III SEQUOIA Arm D cohort results, published in the Journal of Clinical Oncology, show zanubrutinib + venetoclax was effective with a favorable safety profile in patients with CLL/SLL, regardless of TP53 mutation status.

Learn more: LymphomaHub.com

#lymphoma #lymsm #MedEd

New publication 📝 A secondary analysis from the phase III HD21 trial, published in The Lancet Group, shows higher rates of gonadal function recovery in men and women with advanced cHL treated with BrECADD vs eBEACOPP.

Learn more: LymphomaHub.com

#lymphoma #lymsm #MedNews #MedEd

🚨 News 🚨
EMA CHMP has recommended the approval of a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy.
Read more: https://loom.ly/1mZhRVY
#lymphoma #lymsm #MedNews

🚨 News 🚨
EMA CHMP has recommended approval for a new subcutaneous formulation of pembrolizumab for approved indications, including classical Hodgkin lymphoma.
Read more: https://loom.ly/Pt5PnW0
#lymphoma #lymsm #MedNews #MedEd

📝 At #ICML18, the Lymphoma Hub symposium “Customizing therapy for MCL” was chaired by Gilles Salles, featuring presentations from Julie Vose, Wojciech Jurczak, and Michael Wang and concluding with an interactive Q&A session.

Learn more: https://loom.ly/5348JN4
#Lymphoma #lymsm #MedEd